2 days ago · TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin. Relaxin is an endogenous protein, expressed at low levels in both men and women that is a pulmonary and systemic vasodilator with lusitropic, anti ...

2 days ago · About TX45, a long-acting Fc-relaxin fusion protein TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin. Relaxin is an endogenous protein, expressed at low levels in both men and women that is a pulmonary ...

Nov 28, 2023 · Tectonic’s TX000045 Fc-relaxin fusion protein (“TX45”) is a potential best-in-class agent, resulting from protein engineering efforts to overcome the human hormone’s biophysical property limitations and achieve optimal pharmacokinetic, target engagement and developability properties. Following completion of dose

Nov 11, 2024 · Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal plasma flow (“RPF”)

2 days ago · What is TX45 and its purpose in treating PH-HFpEF? TX45 is a long-acting Fc-relaxin fusion protein aimed at improving left ventricular function and pulmonary hemodynamics in PH-HFpEF...

The Phase 1 study with TX45 in patients with Group 2 PH with HFpEF is a single dose, open-label study to evaluate safety, tolerability and acute hemodynamic effects of intravenous administration of TX45.

Nov 11, 2024 · Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal ...

Jul 30, 2024 · TX45 is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF), a serious condition ...

2 days ago · About TX45, a long-acting Fc-relaxin fusion protein TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein ...

2 days ago · In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events. In the overall study population, TX45 achieved a 17.9% reduction in pulmonary capillary ...